Skull immune signal linked to progressive MS

Credibility

Interest

Key Takeaway

A protein linked to immune activity is higher in the skull bone marrow of people with progressive MS and is tied to worse disability and brain damage.

What They Found

Researchers used a special brain and bone scan to look at a protein called TSPO, which signals immune cell activity, in the skull bone marrow of people with MS and healthy volunteers. People with secondary progressive MS (a later, more steadily worsening form) showed much higher TSPO in many skull regions than people with relapsing-remitting MS or healthy people. Higher TSPO in the skull was linked to worse disability scores and poorer thinking test results, and to smaller white matter in the brain. In relapsing-remitting MS (an earlier, relapsing form), skull TSPO looked similar to healthy people. This suggests the skull bone marrow may be involved in ongoing inflammation that relates to disease progression.

Who Should Care and Why

People with progressive MS should care because the finding points to a possible new place (skull bone marrow) where harmful immune activity may be happening, which could help explain worsening symptoms. Caregivers may find it useful because it points toward new ways doctors might track or treat progression — like checking the skull for signs of inflammation, similar to how you might check the oil light in a car to monitor the engine. Clinicians and researchers may use this information to develop tests or treatments that target immune cells in the skull marrow rather than (or in addition to) the brain. Patients worried about worsening mobility or thinking might find comfort that scientists are finding new clues about why progression happens. This could eventually affect choices about treatments or monitoring if validated in future studies.

Important Considerations

The study shows an association but does not prove that skull TSPO causes MS worsening — it might be a sign of damage rather than the driver of damage. The scans used a tracer that marks general immune activity, not only the specific harmful cells, so higher signal could reflect several cell types or processes. The results need confirmation in larger studies and over time to see if skull TSPO predicts future decline or changes with treatment.

AI-generated summary — for informational purposes only, not medical advice

Categories:

MS Progression Early Research MS Genetics

Article Topics:

MRITSPO PETatrophymultiple sclerosisprogressionskull bone marrow

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Brain : a journal of neurology often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News